72
Participants
Start Date
July 25, 2018
Primary Completion Date
April 3, 2020
Study Completion Date
September 9, 2020
Dupilumab
Dupilumab, an interleukin (IL)-4 receptor alpha (IL-4Rα) antagonist, is indicated for the treatment of adult patients with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. (FDA approved on March 28, 2017.)
Placebo
Placebo will contain the identical formulation as the dupilumab formulation without the active mAb and will be given by exactly the same route and schedule through Day 28.
University of Rochester Medical Center, Rochester
University of Pennsylvania, Philadelphia
Duke University, Durham
University of Florida, Gainesville
National Jewish Health, Denver
Children's Hospital Los Angeles, Los Angeles
University of California San Diego, La Jolla
Stanford University, Stanford
Oregon Health Sciences University, Portland
Collaborators (1)
Regeneron Pharmaceuticals
INDUSTRY
Sanofi
INDUSTRY
Atopic Dermatitis Research Network
OTHER
Rho Federal Systems Division, Inc.
INDUSTRY
National Institute of Allergy and Infectious Diseases (NIAID)
NIH